Abstract
Current therapeutic drugs for the treatment of bone loss-associated disorders such as osteoporosis and metastatic bone disease have limited clinical outcomes, namely in terms of efficiency and sustainability. Given the ageing of population in developed countries and the cumulative costs with treatment, bone loss-associated disorders represent a major socioeconomic burden worldwide. In this review, the therapeutic agents targeting bone loss tested in clinical and pre-clinical trials are summarized, as well as the challenges encountered by clinicians and patients. In an effort to attain costeffective clinical outcomes, potential cellular and signalling targets are disclosed.
Keywords: Bone loss, therapy, anabolic agents, anti-resorptive agents, clinical trials, osteoclasts, osteoblasts.
Current Drug Targets
Title:Therapeutic Drugs in Bone Loss-Associated Disorders: Clinical Outcomes and Challenges
Volume: 18 Issue: 6
Author(s): Daniela M. Sousa, Ines S. Alencastre, Luís Leitao, Estrela Neto, Cecilia J. Alves and Meriem Lamghari
Affiliation:
Keywords: Bone loss, therapy, anabolic agents, anti-resorptive agents, clinical trials, osteoclasts, osteoblasts.
Abstract: Current therapeutic drugs for the treatment of bone loss-associated disorders such as osteoporosis and metastatic bone disease have limited clinical outcomes, namely in terms of efficiency and sustainability. Given the ageing of population in developed countries and the cumulative costs with treatment, bone loss-associated disorders represent a major socioeconomic burden worldwide. In this review, the therapeutic agents targeting bone loss tested in clinical and pre-clinical trials are summarized, as well as the challenges encountered by clinicians and patients. In an effort to attain costeffective clinical outcomes, potential cellular and signalling targets are disclosed.
Export Options
About this article
Cite this article as:
Sousa M. Daniela, Alencastre S. Ines, Leitao Luís, Neto Estrela, Alves J. Cecilia and Lamghari Meriem, Therapeutic Drugs in Bone Loss-Associated Disorders: Clinical Outcomes and Challenges, Current Drug Targets 2017; 18 (6) . https://dx.doi.org/10.2174/1389450117666160709024547
DOI https://dx.doi.org/10.2174/1389450117666160709024547 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Combined Chemotherapy or Biotherapy with Jasmonates: Targeting Energy Metabolism for Cancer Treatment
Current Pharmaceutical Biotechnology Involvement of Adipogenic Potential of Human Bone Marrow Mesenchymal Stem Cells (MSCs) in Osteoporosis
Current Stem Cell Research & Therapy Past, Present, and Future of Targeting Ras for Cancer Therapies
Mini-Reviews in Medicinal Chemistry Bio-analytical Identification of Key Genes that Could Contribute to the Progression and Metastasis of Osteosarcoma
Current Bioinformatics <i>In Vitro</i> Anti-proliferative Properties of Flavonoids Isolated from <i>Artocarpus Heterophyllus</i> on Cancer Cell Lines
The Natural Products Journal Flavonoids Active Against Osteosarcoma: A Review of the Molecular Mechanisms Involved
Current Pharmaceutical Design Nanomedicine as a Strategy for Natural Compound Delivery to Prevent and Treat Cancers
Current Pharmaceutical Design Mycotherapy of Cancer: An Update on Cytotoxic and Antitumor Activities of Mushrooms, Bioactive Principles and Molecular Mechanisms of their Action
Current Topics in Medicinal Chemistry Cellular Systems Biology Profiling Applied to Cellular Models of Disease
Combinatorial Chemistry & High Throughput Screening Potential Use of Vanadium Compounds in Therapeutics
Current Medicinal Chemistry Peptides or Small Molecules? Different Approaches to Develop More Effective CDK Inhibitors
Current Medicinal Chemistry Human Mesenchymal Stem Cells (hMSCs) as Targets of DNA Damaging Agents in Cancer Therapy
Current Cancer Drug Targets Sida cordifolia, a Traditional Herb in Modern Perspective – A Review
Current Traditional Medicine Anti-cancer and Anti-angiogenic Properties of Various Natural Pentacyclic Tri-terpenoids and Some of their Chemical Derivatives
Current Organic Chemistry Withdrawal Notice: Role, Significance and Association of microRNA-10a/b in Physiology of Cancer
MicroRNA Advances of Phenoxazines: Synthesis, Reactivity and Their Medicinal Applications
Current Medicinal Chemistry Pro-apoptotic Activity of BH3-only Proteins and BH3 Mimetics: from Theory to Potential Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry MDM2 Increases Drug Resistance in Cancer Cells by Inducing EMT Independent of p53
Current Medicinal Chemistry Editorial (Thematic Issue:Nanotechnology for Drug Delivery: Part III)
Current Pharmaceutical Design Targeting the Mevalonate Pathway for Improved Anticancer Therapy
Current Cancer Drug Targets